Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

DarioHealth (DRIO) EBITDA Margin (2016 - 2025)

DarioHealth filings provide 12 years of EBITDA Margin readings, the most recent being 195.99% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 3474.0% to 195.99% in Q4 2025 year-over-year; TTM through Dec 2025 was 276.11%, a 12455.0% decrease, with the full-year FY2025 number at 276.11%, down 12455.0% from a year prior.
  • EBITDA Margin hit 195.99% in Q4 2025 for DarioHealth, up from 376.57% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 83.97% in Q4 2022 to a low of 480.5% in Q3 2023.
  • Median EBITDA Margin over the past 5 years was 270.61% (2022), compared with a mean of 264.59%.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 45011bps in 2022 and later tumbled -51279bps in 2023.
  • DarioHealth's EBITDA Margin stood at 366.14% in 2021, then surged by 123bps to 83.97% in 2022, then crashed by -611bps to 428.82% in 2023, then soared by 62bps to 161.24% in 2024, then dropped by -22bps to 195.99% in 2025.
  • The last three reported values for EBITDA Margin were 195.99% (Q4 2025), 376.57% (Q3 2025), and 345.73% (Q2 2025) per Business Quant data.